paediatrics Brussels 17

SJCRH study (Lucas )

• Prognostic relevance of Curie score with advances in systemic therapy requires • re-evaluation • • Early metastatic site failure is usually at a new site while prior/old MSF usually occurs later • • Inability to complete systemic therapy & presence of lung metastases are risk factors for progression at new metastatic sites • • Persistent MIBG avid disease is insufficiently controlled with adjuvant doses • (21.6-23.4 Gy) • • MIBG avidity is a reasonable way to select high risk sites for recurrence